FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2473420009> ?p ?o ?g. }

• W2473420009 endingPage "3514" @default.
• W2473420009 startingPage "3514" @default.
• W2473420009 abstract "3514 Background: In contrast to BRAFV600 mutated (BRAFm) advanced melanoma, BRAFm colorectal carcinoma (CRC) does not respond to BRAF inhibitors due to strong feedback activation of the epidermal growth factor receptor (EGFR) upon BRAF inhibition. However, combining a BRAF and an EGFR inhibitor resulted in strong synergistic activity with complete inhibition of tumor growth in vitro and in vivo. The addition of a phosphatidylinositol 3-kinase (PI3K) inhibitor increased synergy. Methods: This is a phase I study evaluating safety, tolerability and anti-tumor activity of encorafenib (LGX818), a highly selective BRAF V600 inhibitor, the EGFR mAb cetuximab, ± the α-specificPI3K inhibitor BYL719 in patients (pts) with advanced BRAFm/KRAS wild-type CRC. Cohorts of pts were treated with escalating doses of oral encorafenib once daily in combination with IV cetuximab (400 mg/m2 loading dose, 250 mg/m2weekly) (dual arm), or with escalating doses of oral encorafenib and oral BYL719 once daily in combination with cetuximab (triple arm). Results: By November 08, 2013, 18 pts were enrolled across four dual combination dose levels: 100 (n = 2), 200 (n = 4), 400 (n = 9) and 450 mg (n = 3) encorafenib. Three pts were enrolled in the triple arm at 200 mg encorafenib, 100 mg BYL719 and cetuximab. Dose escalation has been completed in the dual arm where a phase 2 dose has been identified; dose finding is ongoing in the triple arm. In the dual arm, 2 dose-limiting toxicities, vomiting grade 3 (400 mg) and QTc prolongation grade 3 (450 mg), were observed, and fatigue (33%) and vomiting (28%) were the most frequently observed treatment-related adverse events. Three partial responses, including one in the triple arm, have been observed and prolonged disease stabilization was frequently achieved including two pts that have remained on treatment for one year. Decrease in carcinoembryonic antigen (CEA) has also been observed. Updated data from the triple arm will be presented. Conclusions: These results indicate that combination treatment of encorafenib and cetuximab ± BYL719 is well tolerated with promising antitumor activity in pts with advanced BRAFm CRC who failed standard treatment. Clinical trial information: NCT01719380." @default.
• W2473420009 created "2016-07-22" @default.
• W2473420009 creator A5000418012 @default.
• W2473420009 creator A5010372361 @default.
• W2473420009 creator A5015509025 @default.
• W2473420009 creator A5015900819 @default.
• W2473420009 creator A5018295447 @default.
• W2473420009 creator A5019002225 @default.
• W2473420009 creator A5019473289 @default.
• W2473420009 creator A5021923655 @default.
• W2473420009 creator A5028020706 @default.
• W2473420009 creator A5028266055 @default.
• W2473420009 creator A5028472820 @default.
• W2473420009 creator A5030657436 @default.
• W2473420009 creator A5036507802 @default.
• W2473420009 creator A5040097130 @default.
• W2473420009 creator A5060558357 @default.
• W2473420009 creator A5062748030 @default.
• W2473420009 creator A5068302495 @default.
• W2473420009 creator A5078332643 @default.
• W2473420009 creator A5079864042 @default.
• W2473420009 creator A5088186975 @default.
• W2473420009 date "2014-05-20" @default.
• W2473420009 modified "2023-10-17" @default.
• W2473420009 title "Phase I study of the selective BRAF^V600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced <i>BRAF</i>-mutant colorectal cancer." @default.
• W2473420009 doi "https://doi.org/10.1200/jco.2014.32.15_suppl.3514" @default.
• W2473420009 hasPublicationYear "2014" @default.
• W2473420009 type Work @default.
• W2473420009 sameAs 2473420009 @default.
• W2473420009 citedByCount "16" @default.
• W2473420009 countsByYear W24734200092014 @default.
• W2473420009 countsByYear W24734200092015 @default.
• W2473420009 countsByYear W24734200092016 @default.
• W2473420009 countsByYear W24734200092017 @default.
• W2473420009 countsByYear W24734200092020 @default.
• W2473420009 countsByYear W24734200092023 @default.
• W2473420009 crossrefType "journal-article" @default.
• W2473420009 hasAuthorship W2473420009A5000418012 @default.
• W2473420009 hasAuthorship W2473420009A5010372361 @default.
• W2473420009 hasAuthorship W2473420009A5015509025 @default.
• W2473420009 hasAuthorship W2473420009A5015900819 @default.
• W2473420009 hasAuthorship W2473420009A5018295447 @default.
• W2473420009 hasAuthorship W2473420009A5019002225 @default.
• W2473420009 hasAuthorship W2473420009A5019473289 @default.
• W2473420009 hasAuthorship W2473420009A5021923655 @default.
• W2473420009 hasAuthorship W2473420009A5028020706 @default.
• W2473420009 hasAuthorship W2473420009A5028266055 @default.
• W2473420009 hasAuthorship W2473420009A5028472820 @default.
• W2473420009 hasAuthorship W2473420009A5030657436 @default.
• W2473420009 hasAuthorship W2473420009A5036507802 @default.
• W2473420009 hasAuthorship W2473420009A5040097130 @default.
• W2473420009 hasAuthorship W2473420009A5060558357 @default.
• W2473420009 hasAuthorship W2473420009A5062748030 @default.
• W2473420009 hasAuthorship W2473420009A5068302495 @default.
• W2473420009 hasAuthorship W2473420009A5078332643 @default.
• W2473420009 hasAuthorship W2473420009A5079864042 @default.
• W2473420009 hasAuthorship W2473420009A5088186975 @default.
• W2473420009 hasConcept C121608353 @default.
• W2473420009 hasConcept C126322002 @default.
• W2473420009 hasConcept C143998085 @default.
• W2473420009 hasConcept C197934379 @default.
• W2473420009 hasConcept C2778375690 @default.
• W2473420009 hasConcept C2779998722 @default.
• W2473420009 hasConcept C2780852908 @default.
• W2473420009 hasConcept C526805850 @default.
• W2473420009 hasConcept C71924100 @default.
• W2473420009 hasConcept C98274493 @default.
• W2473420009 hasConceptScore W2473420009C121608353 @default.
• W2473420009 hasConceptScore W2473420009C126322002 @default.
• W2473420009 hasConceptScore W2473420009C143998085 @default.
• W2473420009 hasConceptScore W2473420009C197934379 @default.
• W2473420009 hasConceptScore W2473420009C2778375690 @default.
• W2473420009 hasConceptScore W2473420009C2779998722 @default.
• W2473420009 hasConceptScore W2473420009C2780852908 @default.
• W2473420009 hasConceptScore W2473420009C526805850 @default.
• W2473420009 hasConceptScore W2473420009C71924100 @default.
• W2473420009 hasConceptScore W2473420009C98274493 @default.
• W2473420009 hasIssue "15_suppl" @default.
• W2473420009 hasLocation W24734200091 @default.
• W2473420009 hasOpenAccess W2473420009 @default.
• W2473420009 hasPrimaryLocation W24734200091 @default.
• W2473420009 hasRelatedWork W1908989187 @default.
• W2473420009 hasRelatedWork W2049754458 @default.
• W2473420009 hasRelatedWork W2280217121 @default.
• W2473420009 hasRelatedWork W2435704186 @default.
• W2473420009 hasRelatedWork W2439403919 @default.
• W2473420009 hasRelatedWork W2898134613 @default.
• W2473420009 hasRelatedWork W3026015583 @default.
• W2473420009 hasRelatedWork W3157508482 @default.
• W2473420009 hasRelatedWork W4292087709 @default.
• W2473420009 hasRelatedWork W4386087407 @default.
• W2473420009 hasVolume "32" @default.
• W2473420009 isParatext "false" @default.
• W2473420009 isRetracted "false" @default.
• W2473420009 magId "2473420009" @default.
• W2473420009 workType "article" @default.